Novo Nordisk Canada launches Ozempic savings card aimed at generic price levels

Novo Nordisk Canada has launched a savings card for Ozempic that is meant to bring the brand-name semaglutide down to roughly the price of generic versions for Canadians who pay out of pocket ^[1]. The card is distributed through Rexall pharmacies and is not available in Quebec ^[1].

It arrives as generic semaglutide spreads through the Canadian market. Dr. Reddy's generic semaglutide reached Canadian pharmacies on May 15, 2026 ^[2]. Health Canada has authorized generic semaglutide injections from Dr. Reddy's and from Canadian manufacturer Apotex, with seven other applications still under review at the time of that report ^[2]. A tracker on the same site now lists three of nine filed generic semaglutide products as approved ^[1]. Apotex later began shipping its product ^[1].

The savings card does not set a public price on its own. Novo Nordisk has not disclosed the size of the discount or the eligibility rules, beyond the Rexall distribution and the Quebec exclusion ^[1].

How Canadian generic pricing is set

Canadian generic prices fall in steps based on how many manufacturers are selling. Mina Tadrous, a pharmacist and drug policy researcher at the University of Toronto, told CBC News that with a single generic, prices fall to 75% of the brand list price; with two, to 50%; and with three or more, to 35% ^[2]. A separate account of Canada's pCPA pricing tiers puts the first entrant at 75% to 85% of brand and the level at 35% once three or more generics are on the market ^[1].

Tadrous estimated to The BMJ that once three generics are available, out-of-pocket costs should reach about C$100 per month ^[2]. Pharmacy prices tracked in Canada currently list brand-name Ozempic at C$86.40 to C$663 and Wegovy at C$270 to C$550 ^[2].

Novo Nordisk's defensive posture

Novo Nordisk is also running an advertising campaign in Canada urging patients to ask for brand-name Ozempic, and Tadrous told The BMJ he expects the company to hold more market share after generic entry than is typical in such situations ^[2].

The company's overall outlook has shifted. Novo Nordisk forecast that 2026 sales would fall between 5% and 13%, ending years of double-digit growth, and its share price fell 17% on the day the guidance was announced ^[2]. CEO Mike Doustdar described 2026 as reflecting "a year of unprecedented pricing pressure" ^[2].

The generic competition in Canada traces back to a lapse: Novo Nordisk stopped paying a C$250 annual patent maintenance fee starting in 2018, according to reporting by The BMJ ^[2]. Tahir Amin, CEO of the Initiative for Medicines, Access & Knowledge, told the BBC the Canadian patent could have been extended until 2028 but was not renewed, saying "somebody dropped the ball … that's why you've got generics in Canada sooner" ^[2]. Novo Nordisk told The BMJ only that "all intellectual property decisions are carefully considered at the global level," and told the BBC the Canadian situation is "a localized situation based on our specific patent timelines and regulatory environment and does not reflect the situation in the United States, where exclusivity remains intact" ^[2].

Why it matters for patients

The pricing change applies to Canada, not the United States. Novo Nordisk retains semaglutide patent protection in the United States until 2032 and in Europe and Japan until 2033, according to The BMJ ^[2]. No US version of this savings card, tied to generic competition, has been reported ^[1].

For Americans who pay cash for Ozempic or Wegovy, nothing in these reports changes US list prices. The Canadian card's discount amount and eligibility terms have not been disclosed, so its real-world value to an uninsured Canadian is not yet established ^[1]. Quebec residents are excluded from the card ^[1].

What happens next

Apotex has begun shipping generic semaglutide, and Sandoz has targeted the third quarter of 2026 for its own version, with Aspen going Canada-first, according to the same reporting ^[1]. Under the tiered framework, a third generic on the market is the point where Canadian generic prices drop to 35% of the brand list price ^[1][2]. Tadrous's estimate of about C$100 per month out of pocket depends on reaching that three-generic threshold ^[2]. Whether Novo Nordisk's savings card continues once that happens has not been reported ^[1].